University of Toledo U.S. Patents

This collection includes United States patents for inventions by UT faculty, students and staff that list UT/MCO/MUO as the original assignee (owner). These patents include those assigned to the University of Toledo as well as to the Medical College of Ohio/Medical University of Ohio prior to the merger in 2006. Only granted patents, not patent applications, are included. Use the 'Search within this Series' box to search for keywords in the authors, titles, or abstracts of the patents.

The University of Toledo, Technology Transfer Website

Gene and method for production of an IgA binding protein
The subject invention concerns novel polynucleotide sequences which code for polypeptides which bind IgA. A further aspect of the invention are hybrid proteins (and genes encoding these hybrid proteins) which comprise binding domains for both IgA and IgG.
IL-12 Stimulation of Neonatal immunity
The present invention relates to a method of inducing a Th1-like response against a pathogen in a neonatal host, which comprises administering to the neonatal host an effective amount of IL-12 and an antigen of the pathogen. Also encompassed by the present invention is a method of overcoming suppression of interferon-? (IFN-?) expression in a neonatal host due to exposure of the neonatal host to a pathogen or an antigen, which comprises administering to the neonatal host an effective amount of IL-12 and the antigen. The present invention also relates to a method of enhancing the cytokine expression against or in response to a pathogen in a neonatal host, which comprises administering to the neonatal host an effective amount of IL-12 and an antigen of the pathogen.
Modified plasminogen activator inhibitor type-1 and methods based thereon
The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (PAI-1) in which two or more amino acid residues that do not contain a sulfhydryl group have been replaced with amino acid residues that contain a sulfhydryl group and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified PAI-1 proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified PAI-1, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic. The modifide PAI-1 molecules of the present invention are useful for the treatment, prophylaxis, management and amelioration of cardiovascular diseases such as, but not limited to those that are related to hyperfibrinolysis, hemophilia, and vessel leakage syndrome.
Modified plasminogen activator inhibitor type-1 molecule and methods based thereon
The present invention relates to a modified plasminogen activator inhibitor type-1 (PAI-1) molecule that displays an increased in vivo half-life of the active form of PAI-1, but is deficient in one or more functional activities as compared to the wild-type PAI-1 protein. The modified PAI-1 molecule that displays an increased half-life further displays at least one of the following functional characteristics: (i) decreased binding activity to at least one of the following molecules: urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and vitronectin (Vn); and (ii) decreased specific activity against at least one of the following molecules: uPA, tPA and Vn. The invention further relates to pharmaceutical compositions comprising modified PAI-1 molecules and methods of using these pharmaceutical compositions for treatment.